Medicare Enrolled
Dr. Donald Richards, MD
Medical Oncology · Tyler, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Richards from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Richards? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Richards
Dr. Donald Richards is a medical oncology in Tyler, TX, with 19 years in practice. Based on federal Medicare data, Dr. Richards performed 116,825 Medicare services across 4,648 unique beneficiaries.
Between the years covered by Open Payments, Dr. Richards received a total of $40,917 from 40 pharmaceutical and/or device companies across 133 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Richards is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 6% volume in TX$ $40,917 industry payments
Medicare Practice Summary
Medicare Utilization ↗116,825
Medicare services
Top 6% in TX for medical oncology
4,648
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,149 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 16,830 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 16,200 | $43 | $136 |
| Nivolumab injection (Opdivo) | 13,080 | $24 | $76 |
| Oxaliplatin chemotherapy injection | 10,700 | $0 | $33 |
| Paclitaxel chemotherapy injection | 10,218 | $0 | $8 |
| Iron sucrose injection (Venofer) | 7,300 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 7,259 | $0 | $3 |
| Daratumumab injection (Darzalex) | 5,940 | $38 | $128 |
| Darbepoetin injection (Aranesp) for anemia | 5,040 | $2 | $20 |
| Dexamethasone injection (steroid) | 2,971 | $0 | $1 |
| Immune globulin infusion (Octagam) | 2,550 | $34 | $233 |
| Anti-nausea injection (fosaprepitant) | 2,250 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 1,800 | $18 | $66 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,500 | $23 | $155 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 986 | $24 | $181 |
| Blood draw (venipuncture) | 979 | $8 | $20 |
| Injection, granisetron hydrochloride, 100 mcg | 960 | $0 | $24 |
| Comprehensive metabolic blood panel | 857 | $10 | $64 |
| Complete blood count (CBC) with differential | 844 | $8 | $36 |
| Injection of additional new drug or substance into vein | 667 | $12 | $108 |
| Anti-nausea injection (Aloxi/palonosetron) | 630 | $1 | $114 |
| Injection, leucovorin calcium, per 50 mg | 539 | $3 | $25 |
| Injection, fluorouracil, 500 mg | 494 | $2 | $13 |
| Office visit, established patient (20-29 min) | 459 | $63 | $250 |
| Administration of chemotherapy into vein, 1 hour or less | 456 | $98 | $707 |
| Injection, carboplatin, 50 mg | 373 | $2 | $300 |
| Injection, zoledronic acid, 1 mg | 346 | $7 | $431 |
| Office visit, established patient (30-39 min) | 273 | $95 | $368 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 264 | $96 | $1,348 |
| Injection, potassium chloride, per 2 meq | 255 | $0 | $1 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 225 | $3 | $373 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 209 | $22 | $157 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 182 | $46 | $313 |
| Cyclophosphamide, 100 mg | 180 | $17 | $203 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 168 | $272 | $2,762 |
| Injection, cisplatin, powder or solution, 10 mg | 157 | $2 | $94 |
| Injection, diphenhydramine hcl, up to 50 mg | 156 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 139 | $48 | $344 |
| Immunoglobulin level test | 129 | $9 | $56 |
| Administration of chemotherapy into vein, each additional hour | 124 | $21 | $161 |
| Injection, magnesium sulfate, per 500 mg | 104 | $1 | $6 |
| Drug injection, under skin or into muscle | 102 | $10 | $96 |
| Iron level test | 99 | $6 | $27 |
| Iron binding capacity test | 99 | $9 | $35 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 99 | $354 | $1,722 |
| Ferritin level test (iron stores) | 97 | $13 | $60 |
| Carcinoembryonic antigen (cea) protein level | 96 | $19 | $99 |
| Magnesium level test | 94 | $7 | $29 |
| Reticulated (young) platelet measurement | 83 | $35 | $143 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 78 | $55 | $211 |
| Ct scan of chest with contrast | 75 | $48 | $821 |
| Unclassified drugs | 75 | $1 | $8 |
| Microscopic examination for white blood cells with manual cell count | 73 | $4 | $22 |
| Complete blood count (CBC), automated | 73 | $6 | $34 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 72 | $69 | $70 |
| Infusion, normal saline solution , 1000 cc | 68 | $2 | $19 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 54 | $137 | $3,675 |
| New patient office visit, complex (60-74 min) | 52 | $164 | $709 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 49 | $16 | $100 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 48 | $124 | $500 |
| Urea nitrogen level to assess kidney function, quantitative | 42 | $4 | $24 |
| CT scan of abdomen and pelvis with contrast | 41 | $170 | $1,067 |
| Irrigation of implanted venous access drug delivery device | 40 | $18 | $114 |
| PSA test (prostate cancer screening) | 38 | $18 | $94 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 33 | $178 | $700 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 32 | $15 | $94 |
| Administration of additional new drug or substance into vein using push technique | 29 | $42 | $289 |
| CT scan of chest, without contrast | 28 | $43 | $686 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $26 | $145 |
| Infusion into a vein for hydration, 31-60 minutes | 25 | $25 | $256 |
| Hospital follow-up visit, moderate complexity | 25 | $56 | $247 |
| Infusion into a vein for hydration, each additional hour | 23 | $10 | $75 |
| Application of on-body injector for under skin injection | 22 | $14 | $96 |
| Ct scan of abdomen and pelvis before and after contrast | 19 | $196 | $1,413 |
| Drawing of blood for a medical problem | 19 | $62 | $264 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 19 | $1 | $19 |
| Ct scan of abdomen and pelvis without contrast | 18 | $76 | $560 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 16 | $1,098 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 15 | $91 | $657 |
| Vitamin B-12 level test | 12 | $15 | $76 |
| New patient office visit (45-59 min) | 12 | $127 | $565 |
| Initial hospital admission, moderate complexity | 11 | $81 | $470 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.1% high complexity
78.4% medium
4.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$40,917
Total received (2018-2024)
Avg $5,845/year across 7 years
Top 24% in TX for medical oncology
40
Companies
133
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$25,371 (62.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11,520 (28.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,026 (9.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,369
2023$3,479
2022$1,222
2021$125
2020$15,566
2019$12,937
2018$5,218
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Ipsen Biopharmaceuticals, Inc
$10,340
Seattle Genetics, Inc.
$5,362
Seagen Inc.
$4,431
AstraZeneca Pharmaceuticals LP
$4,066
JAZZ PHARMACEUTICALS INC.
$2,871
F. Hoffmann-La Roche AG
$2,329
Taiho Oncology, Inc.
$2,192
Bayer HealthCare Pharmaceuticals Inc.
$1,645
ARRAY BIOPHARMA INC
$1,591
Incyte Corporation
$1,585
Aadi Bioscience, Inc.
$1,000
Amgen Inc.
$535
Genentech USA, Inc.
$264
ABBVIE INC.
$243
Janssen Biotech, Inc.
$241
PFIZER INC.
$221
Novartis Pharmaceuticals Corporation
$208
Pharmacyclics LLC, An AbbVie Company
$194
Tempus AI, Inc
$147
Exelixis Inc.
$146
E.R. Squibb & Sons, L.L.C.
$130
Puma Biotechnology, Inc.
$125
Ethicon US, LLC
$122
Lilly USA, LLC
$104
SANOFI-AVENTIS U.S. LLC
$100
Myriad Genetic Laboratories, Inc.
$98
Takeda Pharmaceuticals U.S.A., Inc.
$93
Celgene Corporation
$77
Merck Sharp & Dohme Corporation
$73
TESARO, Inc.
$63
Gilead Sciences, Inc.
$51
SOBI, INC
$40
Kite Pharma, Inc.
$40
Astellas Pharma US Inc
$38
Immunocore Limited
$29
Regeneron Healthcare Solutions, Inc.
$29
GENZYME CORPORATION
$28
Stemline Therapeutics Inc.
$27
Pharmacyclics LLC, an AbbVie Company
$20
Iovance Biotherapeutics, Inc.
$17
Top 3 companies account for 49.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · Amtagvi · BOSULIF · BRAFTOVI · CALQUENCE · Cabometyx · DARZALEX · DOPTELET · ELITEK · EPKINLY · ERBITUX · ERLEADA · Erleada · FYARRO · GAZYVA · IMBRUVICA · IMFINZI · IMJUDO · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUTATHERA · LYNPARZA · Lonsurf · MYRISK · NEUWAVE Flex Microwave Ablation System · NINLARO · Nerlynx · Nubeqa · ONIVYDE · OPDIVO · Onivyde · Orserdu · PEMAZYRE · Padcev · Prolia · ROZLYTREK · SARCLISA · SOMATULINE DEPOT · SUTENT · Stivarga · TABRECTA · TAGRISSO · TECENTRIQ · VENCLEXTA · VERZENIO · VONJO · VYXEOS · XALKORI · XT CDX · XTANDI · ZANIDATAMAB · ZEJULA · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (62%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $35 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
1.7
County median income
$71,923
Nearest hospital
UT HEALTH EAST TEXAS TYLER REGIONAL HOSPITAL
3.0 mi
3.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Richards is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), and consulting-driven industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Richards experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Richards performed 16,830 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Richards receive payments from pharmaceutical companies?
Yes. Dr. Richards received a total of $40,917 from 40 companies across 133 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Richards's costs compare to other medical oncologys in Tyler?
Dr. Richards's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Richards) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Tyler
Browse medical oncologys in Tyler ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Ipsen Biopharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Ipsen Biopharmaceuticals, Inc.
By company
Seattle Genetics, Inc. Payments to Doctors
See all physicians who received payments from Seattle Genetics, Inc..
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology